Taysha Gene Therapies is trading 5.24% lower at $3.79; no specific company announcement or verified catalyst was identified for the October 23, 2026 decline.
- The company’s latest listed release was October 1, about clinical-program presentations.
- Broader markets were mixed-to-lower: the Dow fell more than 1%, while the S&P 500 and Nasdaq fell less than 0.5%.
- Earlier premarket strength reversed; no cause was confirmed, and trading volume information was unavailable.